TCG Advisors’s iShares Biotechnology ETF IBB Stock Holding History

TCG Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,601	Closed	-$492K	–	50
2020 Q2	$492K	Buy	+3,601	New	+$459K	0.27%	82

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

TCG Advisors's IBB Position: Q3 2020 in Review

TCG Advisors sold out of iShares Biotechnology ETF (IBB) in Q3 2020, closing a stake of 3,601 shares — an estimated $492K sold.

TCG Advisors first reported a position in IBB in Q2 2020 and held it in 1 quarter. The position peaked at $492K in Q2 2020. 784 funds tracked by Wall St. Rank hold IBB as of Q3 2020.

TCG Advisors reported no remaining iShares Biotechnology ETF position as of Q3 2020 after selling out during the quarter.
TCG Advisors sold 3,601 iShares Biotechnology ETF shares in Q3 2020, an estimated $492K.
TCG Advisors first reported a position in iShares Biotechnology ETF in Q2 2020 and held it in 1 quarter.
TCG Advisors's iShares Biotechnology ETF position peaked at $492K in Q2 2020.
784 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2020.

Based on TCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.